Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
$3.28
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.28
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)3.35M
Market Cap
$345.95M
Enterprise Value$335.29M
Total Cash (Recent Filing)$132.94M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding95,697,685
10 Day Avg. Volume2,870,024
30 Day Avg. Volume3,349,191
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.35K
Enterprise Value/Ebitda-3.80
Forecast
1Y Price Target
$6.57Price Target Upside100.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Expanded-access Clinical OutcomesPatients treated through expanded-access programs often discontinued intravenous glucose and parenteral nutrition while on the drug, demonstrating meaningful clinical responses in a controlled setting that support continued development.
Pharmacology And BiomarkersBiomarker increases consistent with target engagement indicate the drug produces measurable pharmacologic effects that support potential therapeutic activity seen in earlier studies.
Unmet Medical Need And Surgical AvoidanceA medical alternative for patients who do not respond to diazoxide could reduce near‑total pancreatectomies and subsequent diabetes risk, creating clear clinical and market opportunity if efficacy is confirmed.
Bears Say
Financing And Dilution RiskAbsence of product revenue and the likely need to raise additional capital pose financing and shareholder dilution risks that could negatively affect valuation and execution of development plans.
Pivotal Trial OutcomeThe Phase 3 study failed to meet its primary and key secondary endpoints, creating significant uncertainty about the drug's ability to deliver clinically meaningful benefit in the target population.
Placebo And Study-effect ConfoundingAn unusually high placebo response, likely amplified by intensive glucose monitoring and trial participation effects, complicates interpretation of efficacy and may limit regulatory confidence in the results.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $345.95M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Sep 10, 2026 which is in 201 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Feb 12, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.033.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rezolute have?
Rezolute has 95,697,685 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went up 5.785%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.57 (100.30% Upside)
$6.57 (100.30% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $206.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 17.2%
Last 30 Days ▼ 17.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.91%
12-Months-Change
Fundamentals
Return on Equity
-74.02%
Trailing 12-Months
Asset Growth
23.77%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$6.57
▲(100.30% Upside)
Technical Analysis
Ownership Overview
11.34% Insiders
40.33% Mutual Funds
0.74% Other Institutional Investors
36.38% Public Companies and Individual Investors